Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor

Though survival outcomes in multiple myeloma patients have improved drastically over the past few decades, there still remains an ongoing need for effective and tolerable treatment options in the relapsed and refractory space. Encouragingly, there have been three recent FDA approvals for triple-clas...

Descripción completa

Detalles Bibliográficos
Autores principales: Joseph, Nisha S, Tai, Yu-Tzu, Anderson, Kenneth C, Lonial, Sagar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380622/
https://www.ncbi.nlm.nih.gov/pubmed/34434061
http://dx.doi.org/10.2147/CPAA.S288840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380622/
https://www.ncbi.nlm.nih.gov/pubmed/34434061
http://dx.doi.org/10.2147/CPAA.S288840

Ejemplares similares